Avadel Pharmaceuticals PLC Total Liabilities
Avadel Pharmaceuticals PLC total liabilities. Based on the latest financial reports, Avadel Pharmaceuticals PLC (AVDL) has total liabilities worth $101.22 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Avadel Pharmaceuticals PLC to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Avadel Pharmaceuticals PLC (1996–2024)
Total liabilities of Avadel Pharmaceuticals PLC from 1996 to 2024. This chart illustrates how Avadel Pharmaceuticals PLC's total liabilities have evolved over time, based on quarterly financial data.
Avadel Pharmaceuticals PLC Competitors by Total Liabilities
The table below lists competitors of Avadel Pharmaceuticals PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Frontken Corporation Bhd
KLSE:0128
|
Malaysia | RM240.37 Million |
|
Íslandsbanki hf.
IC:ISB
|
Iceland | Ikr1.47 Trillion |
|
John Wiley & Sons
NYSE:WLY
|
USA | $1.81 Billion |
|
Compania Cervecerias Unidas SA
SN:CCU
|
Chile | CL$2.03 Trillion |
|
First Commonwealth Financial
NYSE:FCF
|
USA | $10.64 Billion |
|
Jushri Technologies Inc Class A
SHE:300762
|
China | CN¥1.64 Billion |
|
Carborundum Universal Limited
NSE:CARBORUNIV
|
India | Rs11.55 Billion |
|
Bayside Land Corporation Ltd
TA:BYSD
|
Israel | ILA7.08 Billion |
Liability Composition Analysis (1996–2024)
This chart breaks down Avadel Pharmaceuticals PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AVDL total assets.
Liquidity & Leverage Metrics
Avadel Pharmaceuticals PLC Total Liabilities Ratios Explained
Avadel Pharmaceuticals PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avadel Pharmaceuticals PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avadel Pharmaceuticals PLC (1996–2024)
The table below shows the annual total liabilities of Avadel Pharmaceuticals PLC from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $90.39 Million | +17.45% |
| 2023-12-31 | $76.96 Million | -50.00% |
| 2022-12-31 | $153.93 Million | -8.93% |
| 2021-12-31 | $169.02 Million | +13.16% |
| 2020-12-31 | $149.37 Million | -17.31% |
| 2019-12-31 | $180.63 Million | -3.67% |
| 2018-12-31 | $187.52 Million | +11.92% |
| 2017-12-31 | $167.54 Million | -17.63% |
| 2016-12-31 | $203.41 Million | +38.27% |
| 2015-12-31 | $147.11 Million | -1.47% |
| 2014-12-31 | $149.31 Million | +18.72% |
| 2013-12-31 | $125.76 Million | +44.88% |
| 2012-12-31 | $86.81 Million | +119.17% |
| 2011-12-31 | $39.61 Million | +3.39% |
| 2010-12-31 | $38.31 Million | -22.50% |
| 2009-12-31 | $49.43 Million | +14.12% |
| 2008-12-31 | $43.31 Million | -7.40% |
| 2007-12-31 | $46.77 Million | +11.72% |
| 2006-12-31 | $41.87 Million | +11.06% |
| 2005-12-31 | $37.70 Million | +30.66% |
| 2004-12-31 | $28.85 Million | -18.02% |
| 2003-12-31 | $35.19 Million | +226.14% |
| 2002-12-31 | $10.79 Million | +1.46% |
| 2001-12-31 | $10.63 Million | +12.21% |
| 2000-12-31 | $9.48 Million | +61.93% |
| 1999-12-31 | $5.85 Million | -22.30% |
| 1998-12-31 | $7.53 Million | +4.63% |
| 1997-12-31 | $7.20 Million | +5.88% |
| 1996-12-31 | $6.80 Million | -- |
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name… Read more